<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="350">
  <stage>Registered</stage>
  <submitdate>1/09/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000278639</actrnumber>
  <trial_identification>
    <studytitle>The Duration of Action of Zoledronate study</studytitle>
    <scientifictitle>A three year randomised, double-blind, placebo-controlled trial to determine the duration of effect of zoledronate on bone turnover markers and on bone density in post menopausal women with osteopenia.</scientifictitle>
    <utrn />
    <trialacronym>DAZE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Post menopausal Osteopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One infusion of 5mg intravenous zoledronate.</interventions>
    <comparator>Placebo.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The time to normalisation of bone turnover markers in the zoledronate treated group where normalisation is defined as when the mean of a bone turnover marker in the zoledronate treated group lies within 20% of the mean value of that marker in the placebo treated group.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between the change in bone turnover markers.</outcome>
      <timepoint>Over 3 years in the zoledronate-treated group compared to the change in the control group.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between the change in spine and hip bone density.</outcome>
      <timepoint>Over 3 years in the zoledronate-treated group compared to the change in the control group.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Postmenopausal 5 yrs or more, bone density T score between -1.0 and -2.0 at lumbar spine or total hip.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Renal impairment (serum creatinine &gt;0.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP &gt; 2x normal limit, primary hyperparathyroidism, previous fragility fracture of the hip or spine. Use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding 12 months, current or past use of bisphosphonate therapy, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Medication was prepared by a doctor not involved with study participants. The medication was then administered by a study nurse who was unaware of the contents. Thus all study personnel with patient contact were blinded.</concealment>
    <sequence>Computer-generated random numbers in variable blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor I Reid</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland Bone Research Group</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 3 year study designed to determine the duration of action of a single dose of intravenous zoledronate.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland University</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Reid</name>
      <address>Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737677</fax>
      <email>i.reid@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Diana Wattie</name>
      <address>Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020</address>
      <phone>+64 9 3078970</phone>
      <fax>+64 9 3737677</fax>
      <email>d.wattie@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>